pretickt

PFE financials

Pfizer Inc. · end-of-day data as of Oct 16, 2026

Pfizer Inc.
PFE · $169B
$29.58+20.5%last 60 sessions · close Oct 16, 2026
$22.64$29.5852 weeks
Hold · 28 analystsPT $27.49 -7.1%
  • P/E vs own+84.3%
  • P/E vs sector+38.8%
  • Target upside-7.1%
  • Off 52w high0.0%
  • Insiders$2.88M
  • FCF yield+6.5%
  • Earnings in18d
  • Trendbullish
  • Sector▲ +16.0%
  • RSI70
  • MA20×50—
  • Volume0.9x
  • Support-3.3%
  • Resistance—

PFE reported revenue of $15.03B for the quarter ended Jun 28, 2026 (Q2 FY2026), up 2.6% from a year earlier. It posted diluted EPS of -$0.04, free cash flow of $302M and a net margin of -1.6%.

Valuation

  • P/E39.1x
  • P/E vs own+84.3%
  • P/E vs sector+38.8%
  • FCF yield+6.5%
  • Market cap$169B

Quarterly results

Q2 FY2026: Revenue +2.6% year over year, free cash flow 2.0% of revenue, operating margin 31.3%.

RevenueFree cash flow
Q3 FY2023Q4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026
Q2 FY2026Jun 28, 2026$15.03B-0.04$302M72.8%31.3%-1.6%
Q1 FY2026Mar 29, 2026$14.45B0.47$2.18B67.3%27.9%18.6%
Q4 FY2025Dec 31, 2025$17.56B-0.29$4.5B70.0%21.0%-9.4%
Q3 FY2025Sep 28, 2025$16.65B0.62$4B74.9%21.3%21.3%
Q2 FY2025Jun 29, 2025$14.65B0.51-$1.2B64.3%24.4%19.9%
Q1 FY2025Mar 30, 2025$13.71B0.52$1.77B71.7%33.7%21.6%
Q4 FY2024Dec 31, 2024$17.76B0.07$5.8B73.0%32.2%2.3%
Q3 FY2024Sep 29, 2024$17.7B0.78$6.06B60.8%28.1%25.3%
Q2 FY2024Jun 30, 2024$13.28B0.00-$2.42B62.1%14.1%0.2%
Q1 FY2024Mar 31, 2024$14.88B0.55$386M70.6%30.6%21.0%
Q4 FY2023Dec 31, 2023$14.57B-0.60$4.2B41.0%-8.7%-22.9%
Q3 FY2023Oct 1, 2023$13.49B-0.42$2.65B21.4%-22.3%-17.7%